Ganaxolone: Phase III data

Marinus said it will discontinue development of ganaxolone to treat focal onset seizures after top-line data from a double-blind, international

Read the full 204 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE